ES2128572T3 - Utilizacion de los derivados de cefem como agentes antimetastaticos. - Google Patents

Utilizacion de los derivados de cefem como agentes antimetastaticos.

Info

Publication number
ES2128572T3
ES2128572T3 ES94921624T ES94921624T ES2128572T3 ES 2128572 T3 ES2128572 T3 ES 2128572T3 ES 94921624 T ES94921624 T ES 94921624T ES 94921624 T ES94921624 T ES 94921624T ES 2128572 T3 ES2128572 T3 ES 2128572T3
Authority
ES
Spain
Prior art keywords
pct
defined above
organic radical
sec
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921624T
Other languages
English (en)
Inventor
Marco Alpegiani
Pierluigi Bissolino
Ettore Perrone
Enrico Pesenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2128572T3 publication Critical patent/ES2128572T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE DERIVADOS CONOCIDOS DE CEFEM DE LA FORMULA (I), EN LA QUE N ES CERO, UNO O DOS; R{SUP,1} ES HIDROGENO O UN RADICAL ORGANICO, R{SUP,2} REPRESENTA HALO O UN RADICAL ORGANICO O R{SUP,1} Y R{SUP,2} JUNTOS Y CON EL ATOMO DE CARBONO C-2 DEL NUCLEO DE CEFEM CONSTITUYEN UN GRUPO CARBOCICLICO O HETEROCICLICO; R{SUP,3} REPRESENTA R{SUP,2} SEGUN SE HA DEFINIDO ARRIBA O UN RADICAL ORGANICO, R{SUP,4} ES BIEN R{SUP,1} O UN GRUPO ORGANICO, R{SUP,5} ES BIEN R{SUP,1} COMO SE HA DEFINIDO ARRIBA O HALO O ALCOXI C{SUB,1}-C{SUB,6}, ALQUILTIO C{SUB,1}-C{SUB,6} O ACILAMINO C{SUB,1}-C{SUB,6}; R{SUP,6} ES R{SUP,2} COMO SE HA DEFINIDO ARRIBA O UN GRUPO ORGANICO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS.
ES94921624T 1993-07-14 1994-06-24 Utilizacion de los derivados de cefem como agentes antimetastaticos. Expired - Lifetime ES2128572T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939314562A GB9314562D0 (en) 1993-07-14 1993-07-14 Use of cephem derivatives as anti-metastatic agents

Publications (1)

Publication Number Publication Date
ES2128572T3 true ES2128572T3 (es) 1999-05-16

Family

ID=10738806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921624T Expired - Lifetime ES2128572T3 (es) 1993-07-14 1994-06-24 Utilizacion de los derivados de cefem como agentes antimetastaticos.

Country Status (15)

Country Link
US (1) US5777104A (es)
EP (1) EP0708779B1 (es)
JP (1) JPH09500118A (es)
KR (1) KR960703599A (es)
AT (1) ATE176235T1 (es)
AU (1) AU680526B2 (es)
CA (1) CA2167194A1 (es)
DE (1) DE69416311T2 (es)
ES (1) ES2128572T3 (es)
GB (1) GB9314562D0 (es)
HU (1) HUT72739A (es)
IL (1) IL110273A0 (es)
PL (1) PL312582A1 (es)
WO (1) WO1995002603A2 (es)
ZA (1) ZA945093B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513818D0 (en) * 1995-07-06 1995-09-06 Pharmacia Spa 7,7-Disubstituted cephem-4-ketones
WO1997007805A1 (en) * 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
EP0859779A4 (en) * 1995-08-31 2000-04-12 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP2926815A1 (en) * 2014-04-03 2015-10-07 Institut Curie New derivatives of cephalosporin for treating cancer
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383987A (ja) * 1989-08-26 1991-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物およびその塩類
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB2266525A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia

Also Published As

Publication number Publication date
AU680526B2 (en) 1997-07-31
ZA945093B (en) 1995-02-22
DE69416311T2 (de) 1999-08-26
US5777104A (en) 1998-07-07
IL110273A0 (en) 1994-10-21
EP0708779B1 (en) 1999-01-27
WO1995002603A3 (en) 1995-03-09
JPH09500118A (ja) 1997-01-07
HUT72739A (en) 1996-05-28
CA2167194A1 (en) 1995-01-26
ATE176235T1 (de) 1999-02-15
PL312582A1 (en) 1996-04-29
AU7227794A (en) 1995-02-13
GB9314562D0 (en) 1993-08-25
DE69416311D1 (de) 1999-03-11
HU9503852D0 (en) 1996-02-28
EP0708779A1 (en) 1996-05-01
WO1995002603A2 (en) 1995-01-26
KR960703599A (ko) 1996-08-31

Similar Documents

Publication Publication Date Title
NZ511394A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69327541D1 (en) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
AR004493A1 (es) Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen.
NO166129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler.
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
ATE73790T1 (de) Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
FI945581A0 (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
ES2128572T3 (es) Utilizacion de los derivados de cefem como agentes antimetastaticos.
ES2138623T3 (es) Derivados de pleuromutilina.
ES2102327A1 (es) Nuevos derivados de 2,2,6,6-tetrametilpiperidina para utilizarse como agentes estabilizantes para materiales organicos contra la luz, el calor, y la oxidacion. n
DE59304311D1 (de) N-substituierte 3-azabicyclo[3.2.0]heptan-derivate als neuroleptika
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
ES2069313T3 (es) Utilizacion de derivados de tiazoloisoindolinona como medicamentos antiviricos.
AU5674894A (en) Azanoradamantanes
ES8304973A1 (es) Un procedimiento para la preparacion de nuevos derivados de tiocarbapenem 3-sustituidos.
FI954218A0 (fi) Bentsopyraaneja kaliumkanavan avaajina
YU200791A (sh) Trifluorometil 1-karba (1-detia) cefemi
ATE148462T1 (de) Isoxazole derivate als lichtschutzmittel
ES2055155T3 (es) Procedimiento para la obtencion de aciloxiacetidinonas opticamente activas.
ATE169907T1 (de) Azaspiroalkan-derivate als therapeutika

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 708779

Country of ref document: ES